Update, April 15, 2026: The FDA has requested additional data from Eli Lilly regarding Foundayo's liver safety profile. This is not a rejection or withdrawal, but it signals that the agency wants more hepatic safety evidence before expanding the drug's label or clearing remaining review questions. Foundayo remains FDA-approved and available. The timeline for any label updates or additional approvals may be affected. We'll update this page as the situation develops.
No fasting. No water restrictions. No needles. Foundayo (orforglipron) arrived on April 1, 2026 as the first oral GLP-1 weight loss pill you can take at any time of day, with food, without food, whenever, and the FDA approved it. That single change removes the biggest barrier that kept millions of people from accessing this class of drugs.
🔑 Key Takeaways
- Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist, the first oral GLP-1 pill with zero food or water restrictions at dosing time
- FDA approved April 1, 2026 by Eli Lilly for chronic weight management in adults with obesity or overweight with a weight-related condition
- ATTAIN-1 Phase 3 trial: 27.3 lbs average weight loss at the highest dose over 72 weeks vs 2.2 lbs for placebo
- Dosing escalates through 6 steps from 0.8mg to 17.2mg, with at least 30 days at each step
- Side effects mirror injectable GLP-1s, mostly GI, with the same class black box warning for thyroid C-cell tumors
- Self-pay starts at $149/month; commercially insured patients can access it for as little as $25/month via LillyDirect
- Weight loss (12.4%) trails tirzepatide (~20%) and retatrutide (~24%), but no injection makes it the entry point for needle-averse patients
This guide covers everything you need to make sense of Foundayo: what it is, how it works, what the trial data actually shows, the full dosing schedule, every documented side effect, who shouldn't take it, what it costs, and how it compares to the injectable GLP-1s already on the market.
What Is Foundayo?
Foundayo is the brand name for orforglipron, a once-daily oral tablet approved for chronic weight management in adults with a BMI of 30 or greater (obesity), or BMI of 27 or greater with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.
What makes it different from every other oral GLP-1 drug that came before it is its molecular structure. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. That one fact changes everything about how it's taken.
Small Molecule vs Peptide: Why It Matters for Oral Dosing
Peptide-based GLP-1 drugs (like semaglutide) are large, fragile molecules that stomach acid destroys before they can reach the bloodstream. To survive the gut, oral semaglutide (Rybelsus/Wegovy tablets) requires an absorption enhancer, must be taken on an empty stomach with no more than 4oz of water, and needs a 30-minute wait before eating. Even with all that, oral bioavailability is low.
Orforglipron is a small molecule, chemically stable, compact, and designed to survive GI digestion without any of those workarounds. You take it like a vitamin: any time, with or without food, no restrictions. Higher and more consistent bioavailability as a result.
How Foundayo Works
Foundayo works by activating GLP-1 receptors throughout the body, the same mechanism as Wegovy, Ozempic, and every other GLP-1 drug. GLP-1 (glucagon-like peptide-1) is a hormone your small intestine releases after eating. It tells the brain you're full, slows gastric emptying, stimulates insulin release, and suppresses glucagon. Foundayo keeps this signal active far longer than natural GLP-1, which is destroyed in about 12 minutes.
The practical result of sustained GLP-1 receptor activation:
- Appetite drops significantly, not just willpower-level reduction, but an actual change in how the brain's hypothalamus processes hunger signals. Food noise quiets. Meals become satisfying on less food.
- Gastric emptying slows, food moves through the stomach more slowly, extending physical fullness and smoothing glucose absorption after meals
- Insulin sensitivity improves, blood sugar spikes flatten, reducing carb-crash-driven hunger between meals
- Caloric intake falls passively, not because of restriction, but because hunger frequency and intensity both decrease
All of this is the same mechanism as Wegovy or Ozempic. The difference with Foundayo is purely in delivery: oral, convenient, no injection technique to learn, no sharps disposal, no refrigeration of pens.
ATTAIN-1 Trial Results: What the Clinical Data Shows
The pivotal study behind Foundayo's FDA approval is the ATTAIN-1 Phase 3 trial (NCT05869903). It enrolled adults with obesity (no type 2 diabetes), running for 72 weeks with orforglipron vs placebo.
ATTAIN-1 Key Results (Highest Dose, 72 Weeks)
- Average weight loss: 27.3 lbs (12.4% of body weight)
- Placebo comparison: 2.2 lbs (0.9%), a 12x difference
- Treatment regimen analysis (including discontinuations): 25.0 lbs (11.2%) vs 5.3 lbs (2.1%) placebo
- Cardiometabolic improvements: Reduced waist circumference, lower non-HDL cholesterol, lower triglycerides, reduced systolic blood pressure
For context on what 27.3 lbs looks like: someone starting at 220 lbs who hits the trial average loses to around 193 lbs over 72 weeks, roughly 0.38 lbs per week. Slow, consistent, and compounding.
The ATTAIN-1 result (12.4%) trails tirzepatide (~20%) and retatrutide (~24%) in magnitude. That gap is real and worth understanding before choosing. But the trial used the highest dose tested, 36mg in the Phase 3 study, while the FDA-approved escalation tops out at 17.2mg for the maintenance phase. Results at the approved maintenance dose will likely be somewhat lower than the trial's top-dose figure. See the GLP-1 peptides comparison for the full efficacy ranking across all drugs in the class.
Foundayo Dosage: The Full Escalation Schedule
Foundayo is taken once daily as a tablet, with or without food, at any time of day. The escalation moves through six steps, with a minimum of 30 days at each dose before stepping up. The slow ramp exists for the same reason all GLP-1 escalations are slow: nausea is the rate-limiting factor.
| Step | Dose | Minimum Duration | Notes |
|---|---|---|---|
| 1 (Start) | 0.8 mg/day | 30 days | Introductory dose, establishing tolerance |
| 2 | 2.5 mg/day | 30 days | First real appetite suppression for most users |
| 3 | 5.5 mg/day | 30 days | Noticeable hunger reduction; GI side effects most common here |
| 4 | 9 mg/day | 30 days | Therapeutic range begins; steady weight loss for most |
| 5 | 14.5 mg/day | 30 days | Increase only if tolerated and more response needed |
| 6 (Max) | 17.2 mg/day | Maintenance | Maximum approved dose |
Important administration notes:
- Swallow tablets whole, do not break, crush, or chew
- If you miss a dose, take it as soon as possible, but do not take two doses in the same day
- If you miss 7 or more consecutive days, contact your prescriber before restarting, do not simply resume
- Store at room temperature (68–77°F), protected from light in the original bottle and carton
Birth Control Interaction, Important
Foundayo may reduce the effectiveness of oral birth control pills (estrogen/progestin). If you take oral contraceptives, your prescriber may recommend a backup or alternative contraception method for 30 days after starting Foundayo and for 30 days after each dose increase. This is not a minor footnote, discuss it explicitly with your provider before starting.
Foundayo Side Effects
The side effect profile closely mirrors injectable GLP-1 medications. This makes sense, it's the same receptor pathway. What may differ is the time course and severity, since oral absorption is slower and more gradual than a weekly subcutaneous injection.
Common Side Effects
These are the most frequently reported and are primarily GI-related:
- Nausea, the most common; typically peaks in the first 2–4 weeks at each new dose level
- Abdominal/stomach pain
- Heartburn and indigestion
- Constipation
- Gas and bloating
- Diarrhea
- Belching
- Vomiting
- Headache
- Fatigue/tiredness
- Hair loss (temporary, telogen effluvium from rapid weight loss, not a direct drug effect)
Most GI side effects are worst during the first 2–4 weeks at a new dose and improve as the body adapts. Eating smaller meals, avoiding high-fat foods on high-symptom days, and staying well hydrated all meaningfully reduce severity.
Serious Side Effects
Stop taking Foundayo and seek immediate medical care if you experience any of the following:
- Pancreatitis: Severe abdominal pain that doesn't go away, with or without nausea or vomiting, potentially radiating to the back. Discontinue immediately and seek emergency care.
- Severe stomach/GI problems: Persistent severe GI symptoms beyond normal adaptation. Report to your provider promptly.
- Dehydration and kidney problems: Prolonged vomiting or diarrhea can cause fluid loss that strains the kidneys. Drink fluids aggressively if GI side effects are active, and seek care if you cannot keep fluids down.
- Serious allergic reactions: Swelling of face, lips, tongue, or throat; difficulty breathing or swallowing; severe rash or itching; fainting. Get emergency help immediately.
- Hypoglycemia (low blood sugar): Risk increases if combining Foundayo with insulin or sulfonylureas (glipizide, glyburide). Signs include dizziness, shakiness, sweating, confusion, fast heartbeat.
- Gallbladder problems: Upper abdominal pain, yellowing of skin or eyes, fever, clay-colored stools. Gallstone risk increases with rapid weight loss.
- Vision changes: Report any changes in vision during treatment, particularly if you have type 2 diabetes.
- Aspiration risk with anesthesia: Foundayo slows gastric emptying, which increases the risk of food entering the lungs during surgical procedures. Tell all healthcare providers you are taking this medication before any scheduled surgery or procedure.
Black Box Warning: Thyroid C-Cell Tumors
Foundayo carries the same class-wide black box warning as all GLP-1 receptor agonists: an increased risk of thyroid C-cell tumors observed in rodent studies. This risk has not been confirmed in human clinical trials, and it is unknown whether Foundayo causes medullary thyroid carcinoma (MTC) in people.
Do not take Foundayo if:
- You or anyone in your family has ever had medullary thyroid carcinoma (MTC)
- You have Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- You have a known serious allergy to orforglipron or any of its inactive ingredients
Warning signs of possible thyroid issues: lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. Report these to your provider immediately.
Who Should Not Take Foundayo
Beyond the contraindications above, Foundayo requires careful consideration in several populations:
- Pregnancy: Foundayo may harm an unborn baby. Use effective contraception while taking it, and stop if you become pregnant. A pregnancy exposure registry exists, contact Eli Lilly at 1-800-545-5979.
- Breastfeeding: Not recommended during treatment. Discuss infant feeding alternatives with your provider.
- History of pancreatitis: Tell your provider before starting.
- Kidney or severe liver problems: Disclose to your prescriber, dose adjustments or monitoring may be needed.
- Gastroparesis: Foundayo slows gastric emptying further, can significantly worsen pre-existing gastroparesis.
- History of diabetic retinopathy: Monitor for vision changes; rapid glycemic improvement can transiently worsen retinopathy in some patients.
Foundayo Cost and Access
This is where Foundayo surprises people, particularly anyone accustomed to the $900–$1,350/month sticker prices of Wegovy and Ozempic.
| Patient Type | Monthly Cost | Access Route |
|---|---|---|
| Commercially insured (eligible) | As low as $25/month | LillyDirect savings program |
| Self-pay (cash pay) | Starting at $149/month (lowest dose) | LillyDirect or retail pharmacy |
| Medicare Part D (eligible) | ~$50/month | Available from July 1, 2026 |
For comparison: Wegovy runs $1,350/month at list price, Zepbound $550–$650/month at the lower vial option. Foundayo's self-pay price of $149/month at the starting dose is a meaningful shift in accessibility, though cost will rise with higher doses, and pricing programs can change.
Coverage and eligibility rules vary by plan. Verify with your insurer and through LillyDirect (lilly.com/lillydirect) before prescribing or filling.
Foundayo vs Injectable GLP-1s: Honest Comparison
The central question most people have: how does it stack up against Wegovy and Zepbound?
| Drug | Form | Mean Weight Loss | Dosing | List Price/mo | Food Restriction |
|---|---|---|---|---|---|
| Foundayo (orforglipron) | Oral tablet | ~12.4% (27.3 lbs) | Once daily | From $149 (self-pay) | None |
| Wegovy (semaglutide) | Weekly injection | ~14.9% | Once weekly | ~$1,350 | None required |
| Zepbound (tirzepatide) | Weekly injection | ~20.2% | Once weekly | ~$550–$650 | None required |
| Oral Wegovy (semaglutide tablet) | Oral tablet | ~15% (early data) | Once daily | TBD | Empty stomach, 30-min wait |
The honest read: Foundayo produces less weight loss than Wegovy and meaningfully less than Zepbound. If maximum fat loss is the primary goal and injections aren't a dealbreaker, the evidence still favors tirzepatide or semaglutide injectable over Foundayo.
Where Foundayo wins:
- No injections, the needle-aversion barrier is real for a significant portion of the population who won't start an injectable even when they would benefit from it
- No food restrictions, unlike oral semaglutide which requires the empty-stomach/water/wait protocol, Foundayo has zero administration complexity
- Cost, at $149/month self-pay vs $1,350 for Wegovy, the accessibility gap is substantial for uninsured patients
- Simplicity, one tablet, any time of day, no injection technique, no pen priming, no sharps disposal
What to Expect Week by Week
Weeks 1–4 (0.8mg): Starting dose. Most people notice mild appetite reduction, similar to the early effects of any GLP-1. GI adjustment is usually minimal at this dose. Weight change is typically 0–2 lbs.
Weeks 5–12 (2.5–5.5mg): Appetite suppression becomes noticeable at 2.5mg. Moving to 5.5mg is when GI side effects are most likely to appear, this is the window where nausea peaks for most users. Scale movement begins in earnest. 1–2 lbs per week is achievable at therapeutic doses.
Weeks 13–20 (5.5–9mg): Entering the therapeutic range. Hunger meaningfully suppressed. GI side effects typically fading from previous dose. Weight loss accumulating steadily.
Weeks 20–52 (9–17.2mg): Escalating to maintenance dose. This is the phase where body composition changes become clearly visible. Monthly weigh-ins show consistent downward trend. Hair shedding may appear around weeks 8–16, this is telogen effluvium from rapid weight loss, not the drug directly, and typically resolves.
Week 52–72: The ATTAIN-1 trial ran to 72 weeks. Long-term use continues to produce results, weight loss slows as you approach a new set point but doesn't reverse while on the medication. The $149/month cost makes long-term adherence far more sustainable than at injectable GLP-1 list prices.